Report Highlights

Market Overview of U.S. Biosimilar Contract Manufacturing

The U.S. biosimilar contract manufacturing market is a specialized segment of the broader biologics CDMO sector, serving sponsors that must prove analytical similarity to a licensed reference product under the Biologics Price Competition and Innovation Act of 2009. The market was valued at USD 2.4 billion in 2024 and is set to reach USD 6.1 billion by 2032. Unlike global CDMO demand, which is weighted toward novel monoclonal antibodies and cell therapies, U.S. biosimilar work centers on high-volume, price-sensitive molecules such as adalimumab, trastuzumab, and pegfilgrastim.

Structurally, American demand differs from the global norm because sponsors are often domestic developers with compressed timelines, and pharmacy benefit managers exert strong influence over which biosimilars achieve formulary access. Facility qualification matters more than in Europe, since FDA pre-license inspections tie each supplier to a specific site. Onshore capacity therefore carries a premium, and U.S.-sited drug substance plants command pricing above Asian equivalents.

Growth Drivers in U.S. Biosimilar Contract Manufacturing

Three country-specific drivers sustain demand. First, the expiry of major reference-product exclusivities keeps the biosimilar filing pipeline full, with adalimumab, ustekinumab, and denosumab products entering the U.S. market since 2023. Second, the Inflation Reduction Act raised Medicare Part B reimbursement for qualifying biosimilars to ASP plus 8 percent of the reference product through 2027, improving sponsor margins and CDMO volume commitments.

Third, the FDA's 2024 draft guidance removing switching study expectations and its 2025 proposal to reduce comparative efficacy studies shorten development timelines for sponsors. Private-label programs run by pharmacy benefit managers, including Cordavis and Quallent Pharmaceuticals, place recurring high-volume orders with domestic contractors.

Market Restraints and Entry Barriers

Facility qualification remains the sharpest barrier. A new mammalian drug substance suite requires three to four years and capital outlays exceeding USD 300 million, while FDA pre-approval inspections under 21 CFR Parts 210 and 211 can delay license approval by months. Entrants must also complete sponsor audit cycles and demonstrate consistent batch comparability before any commercial award is granted.

Incumbent advantages are pronounced. Lonza, Fujifilm Diosynth, and Samsung Biologics hold multi-year slot agreements with large sponsors, leaving limited uncommitted capacity in the market. Pricing pressure from pharmacy benefit managers compresses margins, while BIOSECURE Act restrictions on certain Chinese CDMOs, including WuXi Biologics, force sponsors with federal exposure to requalify their supply chains.

Market Opportunities in U.S. Biosimilar Contract Manufacturing

Near-term openings concentrate in fill-finish and analytical services, where U.S. capacity remains tight. Sponsors launching denosumab and aflibercept biosimilars require prefilled syringe and vial finishing, a segment estimated at USD 0.7 billion in 2024. Contractors that offer validated aseptic lines with rapid technology transfer capture this demand first.

Second, onshore manufacturing incentives create openings for contractors with NIIMBL collaborations in Newark, Delaware, and for state-level packages supporting expansion in North Carolina's Research Triangle. Third, rising Medicare biosimilar uptake favors CDMOs offering dual-source supply, a capability that allows sponsors to satisfy PBM contracts without single-site risk.

Market at a Glance

Leading Market Participants

• Lonza
• Samsung Biologics
• Fujifilm Diosynth Biotechnologies
• Thermo Fisher Scientific
• AGC Biologics
• Catalent
• Emergent BioSolutions
• National Resilience
• WuXi Biologics
• Lotte Biologics

Regulatory and Policy Environment

The Biologics Price Competition and Innovation Act of 2009 establishes the 351(k) pathway, and the FDA administers biosimilar approvals through the Center for Drug Evaluation and Research. Manufacturers must comply with current good manufacturing practice under 21 CFR Parts 210, 211, and 600 to 680, and BsUFA III sets a ten-month review goal for original 351(k) applications. Interchangeability designation requires additional evidence, although the FDA's 2024 draft guidance removed switching study expectations for most products.

Pricing and reimbursement sit under the Centers for Medicare and Medicaid Services, which administers the IRA biosimilar add-on payment and the Part D redesign effective 2025. The Manufacturing USA network, including NIIMBL, provides federal R&D support for domestic bioprocessing. The Section 232 pharmaceutical investigation launched in 2025 is reshaping tariff exposure on imported drug substances.

Long-Term Outlook for U.S. Biosimilar Contract Manufacturing

By 2032 the U.S. biosimilar contract manufacturing market will reach USD 6.1 billion, with drug substance and fill-finish leading volume growth. Monoclonal antibodies will remain the dominant molecule class, and CDMOs with dual-site U.S. capacity will capture most new sponsor awards. Demand for domestic supply will outpace import-dependent models as tariff and security rules tighten.

Consolidation among mid-tier CDMOs is the expected outcome as sponsors favor scale and regulatory track record. Volume previously routed to restricted Chinese suppliers will migrate to Lonza, Samsung Biologics, and Fujifilm Diosynth. Entrants that secure FDA-inspected sites by 2028 will hold durable positions in the market.